跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
T-COVID
首页
药物
T-COVID
T-COVID
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
COMBATING COVID-19 USING ENGINEERED INKT CELLS
EP 4210717 A4
申请人: THE REGENTS OF UNIV OF CALIFORNIA
优先权: 2020
CN
EP
US
WO
4 件公开
BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE
US 2024269266 A1
申请人: UNIV CALIFORNIA
优先权: 2024
US
4 件公开
PHARMACEUTICAL COMPOSITION FOR PREVENTING CYTOKINE STORM
EP 4292593 A4
申请人: UNIV KINKI
优先权: 2021
EP
US
WO
3 件公开
A BACTERIOPHAGE-BASED, NEEDLE AND ADJUVANT-FREE, MUCOSAL COVID-19 VACCINE
EP 4514386 A4
申请人: UNIV AMERICA CATHOLIC
优先权: 2022
EP
US
WO
3 件公开
VIRALLY EDUCATED T CELLS
EP 4805035 A1
申请人: IMMUNITYBIO INC
优先权: 2023
EP
US
WO
3 件公开
COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US 11191827 B1
申请人: TEVOGEN BIO INC
优先权: 2020
US
3 件公开
PEPTIDE FOR THE TREATMENT OF CYTOKINE STORM SYNDROME
EP 4137144 A2
申请人: CT INGENIERIA GENETICA BIOTECNOLOGIA
优先权: 2020
CN
EP
2 件公开
Methods and compounds for treating effects of COVID-19 disease
US 11628197 B2
申请人: BIOVED PHARMACEUTICALS INC
优先权: 2020
CN
US
2 件公开
ENGINEERED GAMMA DELTA T CELLS AND METHODS OF MAKING AND USING THEREOF
EP 4267150 A4
申请人: THE REGENTS OF UNIV OF CALIFORNIA
优先权: 2020
CN
EP
2 件公开
USE OF COMPOUND, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IMMUNE OR METABOLIC DISORDERS, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ILLNESSES CAUSED BY OR ASSOCIATED WITH VIRUSES
EP 4282425 A4
申请人: PROTEIMAX BIOTECNOLOGIA LTDA
优先权: 2021
EP
WO
2 件公开
第 1 / 5 页
上一页
下一页
药物
反馈